Prosight Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Prosight Management’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-298,900	Closed	-$404K	–	42
2021 Q4	$404K	Buy	+298,900	New	+$707K	0.24%	35
2021 Q2	–	Sell	-117,621	Closed	-$402K	–	52
2021 Q1	$402K	Buy	+117,621	New	+$2.22M	0.33%	34

Other funds holding ODT

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Prosight Management's ODT Position: Q1 2022 in Review

Prosight Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 298,900 shares — an estimated $404K sold.

Prosight Management first reported a position in ODT in Q1 2021 and held it in 2 quarters. The position peaked at $404K in Q4 2021. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

Prosight Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Prosight Management sold 298,900 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $404K.
Prosight Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
Prosight Management's Odonate Therapeutics, Inc. Common Stock position peaked at $404K in Q4 2021.
8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Prosight Management's 13F filing for Q1 2022, filed 16 May 2022.